Maxi Investments CY Ltd purchased a new position in Replimune Group, Inc. (NASDAQ:REPL – Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 42,000 shares of the company’s stock, valued at approximately $556,000.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Quantinno Capital Management LP increased its holdings in shares of Replimune Group by 782.7% in the first quarter. Quantinno Capital Management LP now owns 108,477 shares of the company’s stock valued at $830,000 after buying an additional 96,188 shares in the last quarter. Montanova Capital LLC lifted its position in shares of Replimune Group by 4.0% during the 2nd quarter. Montanova Capital LLC now owns 4,389,836 shares of the company’s stock valued at $48,595,000 after acquiring an additional 168,000 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Replimune Group during the 1st quarter worth $921,000. Squarepoint Ops LLC bought a new stake in shares of Replimune Group during the 2nd quarter worth $1,454,000. Finally, Deutsche Bank AG bought a new stake in shares of Replimune Group during the 2nd quarter worth $857,000. 92.53% of the stock is owned by institutional investors and hedge funds.
Replimune Group Trading Up 8.8%
Replimune Group stock opened at $12.47 on Tuesday. The company has a 50 day moving average price of $13.48 and a 200 day moving average price of $9.19. Replimune Group, Inc. has a 52 week low of $1.50 and a 52 week high of $16.33. The company has a debt-to-equity ratio of 1.00, a quick ratio of 5.23 and a current ratio of 5.23. The firm has a market capitalization of $1.17 billion, a price-to-earnings ratio of -3.96 and a beta of 0.93.
Replimune Group (NASDAQ:REPL – Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.03). Research analysts forecast that Replimune Group, Inc. will post -2.82 EPS for the current year.
Insiders Place Their Bets
In other news, CEO Sushil Patel sold 39,341 shares of Replimune Group stock in a transaction on Monday, August 10th. The stock was sold at an average price of $12.97, for a total transaction of $510,252.77. Following the transaction, the chief executive officer owned 708,151 shares in the company, valued at approximately $9,184,718.47. The trade was a 5.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Konstantinos Xynos sold 11,447 shares of the company’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $12.97, for a total value of $148,467.59. Following the transaction, the insider directly owned 224,215 shares in the company, valued at $2,908,068.55. The trade was a 4.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 79,124 shares of company stock worth $1,038,364. 5.40% of the stock is currently owned by corporate insiders.
Analysts Set New Price Targets
REPL has been the topic of a number of recent analyst reports. BMO Capital Markets raised Replimune Group from an “underperform” rating to an “outperform” rating and set a $16.00 target price on the stock in a research report on Tuesday, June 30th. Wedbush raised Replimune Group from a “neutral” rating to an “outperform” rating and set a $12.00 target price for the company in a report on Friday, August 7th. Piper Sandler upgraded Replimune Group from a “hold” rating to a “strong-buy” rating in a research report on Friday, July 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Replimune Group in a research note on Monday, October 5th. Finally, Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $11.00 to $17.00 in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.00.
Check Out Our Latest Research Report on Replimune Group
About Replimune Group
Replimune Group, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to stimulate the immune system to recognize and attack tumors. The company’s approach focuses on oncolytic immunotherapy, using genetically engineered viruses intended to selectively infect and destroy tumor cells while also activating broader antitumor immune responses.
Replimune’s lead product candidate is RP1, also known as vusolimogene oderparepvec, an engineered oncolytic herpes simplex virus type 1 designed to replicate within tumors and promote systemic immune activity.
Featured Articles
- Five stocks we like better than Replimune Group
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.
